Cargando…
Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
Programmed death-1/programmed death ligand-1 (PD-1/PD-L1) based immunotherapy is a revolutionary cancer therapy with great clinical success. The majority of clinically used PD-1/PD-L1 inhibitors are monoclonal antibodies but their applications are limited due to their poor oral bioavailability and i...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077906/ https://www.ncbi.nlm.nih.gov/pubmed/33906641 http://dx.doi.org/10.1186/s12935-021-01946-4 |